A working list of startups operating across Florida, with ecosystem organizations available as separate views. Search, sort, filter — submit additions anytime.
16 of 1504
#Company↑SectorStageFoundedDescriptionRegion
001
Adze Biotechnology
Adze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers. It has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic. The company was founded in 2019 and is based in Coral Gables, Florida.
Biotechnology—2019Adze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers. It has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic. The company was founded in 2019 and is based in Coral Gables, Florida.MIA→
002
Ambulero
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
Biotechnology—2019Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.MIA→
003
ASP Isotopes
ASP Isotopes is a pre-commercial stage advanced materials company that develops isotope enrichment technology for the medical, green energy, and industrial sectors
Biotechnology—2021ASP Isotopes is a pre-commercial stage advanced materials company that develops isotope enrichment technology for the medical, green energy, and industrial sectorsMIA→
004
CellVax Therapeutics Inc.
CellVax Therapeutics is a privately-held clinical-stage company developing autologous anticancer vaccines
Biotechnology—2020CellVax Therapeutics is a privately-held clinical-stage company developing autologous anticancer vaccinesMIA→
005
Empowered Diagnostics
Empowered Diagnostics delivers innovative diagnostic tests backed by experts in healthcare and biotechnology. The company is driven by a mission to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests.
Biotechnology—2017Empowered Diagnostics delivers innovative diagnostic tests backed by experts in healthcare and biotechnology. The company is driven by a mission to empower people with the knowledge and confidence to understand their health through reliable, affordable, high-quality tests.MIA→
006
Gibson Oncology
Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.
Biotechnology—2018Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.MIA→
007
Gradian Diagnostics
Gradian Diagnostics is a biotechnology company that focuses on developing Next-Gen medical and diagnostics technologies. Its philosophy is to take a practical approach to develop its portfolio. The company believes that inspiration must always be backed up by a heavy dose of quantitative evidence and apply hard-nosed management fundamentals to ensure science actually turns into commercially successful products that make a the difference in the lives of patients. The company was founded in 2018 and is headquartered in Miami Beach, Florida.
Biotechnology—2018Gradian Diagnostics is a biotechnology company that focuses on developing Next-Gen medical and diagnostics technologies. Its philosophy is to take a practical approach to develop its portfolio. The company believes that inspiration must always be backed up by a heavy dose of quantitative evidence and apply hard-nosed management fundamentals to ensure science actually turns into commercially successful products that make a the difference in the lives of patients. The company was founded in 2018 and is headquartered in Miami Beach, Florida.MIA→
008
Innovative Genetics
Innovative Genetics is building the infrastructure layer behind the next wave of compliant therapeutics. We develop and license BioIP—fast-acting formulations, nationally trademarked brand systems, compliant packaging, and deployable production infrastructure—designed for scale, structured for recurring revenue, and protected by intellectual property. Our model is entirely non-substance-touching, enabling operators in legal U.S. markets to commercialize without federal exposure or capital-heavy overhead. We generate revenue through licensing, royalties, and infrastructure leasing—without cultivation, manufacturing, or retail.
Biotechnology—2017Innovative Genetics is building the infrastructure layer behind the next wave of compliant therapeutics. We develop and license BioIP—fast-acting formulations, nationally trademarked brand systems, compliant packaging, and deployable production infrastructure—designed for scale, structured for recurring revenue, and protected by intellectual property. Our model is entirely non-substance-touching, enabling operators in legal U.S. markets to commercialize without federal exposure or capital-heavy overhead. We generate revenue through licensing, royalties, and infrastructure leasing—without cultivation, manufacturing, or retail.MIA→
009
Marizyme
Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.
Biotechnology—2018Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need for higher mortality and costs in the acute care space. The company's first product candidates are derived from a broad intellectual property portfolio around a novel system of proteolytic enzymes called ProteomeX (previously referred to as Krillase Technology). Marizyme completed the acquisition of these assets and intends to immediately develop several product candidates that will address unmet medical needs in the acute care setting.MIA→
010
Myosin Therapeutics
Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders. The company specializes in molecular machines that turn energy into mechanical work inside cells, enabling doctors to treat various disease states, including cancer, and focuses on developing innovative drugs that target cellular motor proteins.
Biotechnology—2020Myosin Therapeutics is a privately-held biopharmaceutical company developing novel medications for CNS-based disorders. The company specializes in molecular machines that turn energy into mechanical work inside cells, enabling doctors to treat various disease states, including cancer, and focuses on developing innovative drugs that target cellular motor proteins.MIA→
011
Nomax Therapeutics
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases. It focuses on life sciences, discoveries in physics and chemistry, and products with no harmful side effects that help patients to restore stability of the body and ensure normal brain functions. The company was founded in 2021 and is headquartered in North Miami Beach, Florida.
Biotechnology—2021Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative diseases. It focuses on life sciences, discoveries in physics and chemistry, and products with no harmful side effects that help patients to restore stability of the body and ensure normal brain functions. The company was founded in 2021 and is headquartered in North Miami Beach, Florida.MIA→
012
Pasithea Therapeutics
Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health. The company is led by renowned immunologists based at Stanford University and their academic research is headed by a top psychiatric academic at King’s College London. The long-term aim is to translate research into clinic-ready drugs. Pasithea Therapeutics' secondary operations focus on establishing anti-depression clinics and mobile clinics across the US and UK, using trained pharmacists to administer intravenous infusions of ketamine. Pasithea has partnered with two successful clinics (THE IV DOC and Zen Health) for immediate exposure in locations across Los Angeles, New York City, and London.
Biotechnology—2020Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health. The company is led by renowned immunologists based at Stanford University and their academic research is headed by a top psychiatric academic at King’s College London. The long-term aim is to translate research into clinic-ready drugs. Pasithea Therapeutics' secondary operations focus on establishing anti-depression clinics and mobile clinics across the US and UK, using trained pharmacists to administer intravenous infusions of ketamine. Pasithea has partnered with two successful clinics (THE IV DOC and Zen Health) for immediate exposure in locations across Los Angeles, New York City, and London.MIA→
013
Psycheceutical
Psycheceutical is a patented delivery technology that provides safe bioavailable psychedelic pharmaceutical medicines. Their goal is to employ next-generation patented Janus particles and novel delivery technologies to bring safety and efficacy to psychedelic compounds for the medical and pharmaceutical industries. These advanced delivery systems allow for safe dosage control and consistent desired results.
Biotechnology—2020Psycheceutical is a patented delivery technology that provides safe bioavailable psychedelic pharmaceutical medicines. Their goal is to employ next-generation patented Janus particles and novel delivery technologies to bring safety and efficacy to psychedelic compounds for the medical and pharmaceutical industries. These advanced delivery systems allow for safe dosage control and consistent desired results.MIA→
014
Syncromune
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.
Biotechnology—2020Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.MIA→
015
Urica Therapeutics
Urica Therapeutics is a clinical-stage biopharmaceutical company focusing on the development and commercialization of pharmaceutical products to treat gout and chronic kidney diseases. Urica is a subsidiary company of Fortress Biotech.
Biotechnology—2021Urica Therapeutics is a clinical-stage biopharmaceutical company focusing on the development and commercialization of pharmaceutical products to treat gout and chronic kidney diseases. Urica is a subsidiary company of Fortress Biotech.MIA→
016
Weo
Weo manufactures a water bottle that is powered by electrolyzing technology that helps water reach its health potential. It developed proprietary biotechnology that uses electrolysis to evolve the filtered water that consumers drink to help improve health from the inside out. The company was founded in 2017 and is based in Miami, Florida.
Biotechnology—2017Weo manufactures a water bottle that is powered by electrolyzing technology that helps water reach its health potential. It developed proprietary biotechnology that uses electrolysis to evolve the filtered water that consumers drink to help improve health from the inside out. The company was founded in 2017 and is based in Miami, Florida.MIA→